Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227832 | 0.96 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL8015441 | 0.92 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL8015641 | 0.92 | SLC10A2 (0.35) | SLC10A2 | |
| SCHEMBL26985891 | 0.91 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL30728307 | 0.91 | SLC10A2 (0.41) | SLC10A2 | |
| SCHEMBL8014474 | 0.90 | SLC10A2 (0.40) | SLC10A2 | |
| SCHEMBL27118537 | 0.90 | SLC10A2 (0.51) | SLC10A2 | |
| SCHEMBL7091381 | 0.89 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL30728281 | 0.89 | SLC10A2 (0.45) | SLC10A2 | |
| SCHEMBL26985934 | 0.89 | SLC10A2 (0.45) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0792268-B1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | WELLCOME FOUND (GB) | 2000-02-23 | — | — | EP | claimed |
| US-5998400-A | Hypolipidemic benzothiazepines | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | claimed |
| EP-0792268-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-09-03 | — | — | EP | claimed |
| WO-1996016051-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-30 | — | — | WO | claimed |
| EP-4551562-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119487013-A | Benzothiepine (di) nitrogen cycloheptatriene compounds Compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118834175-A | Benzothiazacycloalkanes Heptatriene compounds use thereof as bile acid modulators | 阿尔比里奥公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-113453753-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-112449637-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2024-02-29 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-0792268-B1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | WELLCOME FOUND (GB) | 2000-02-23 | — | — | EP | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| US-5998400-A | Hypolipidemic benzothiazepines | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0792268-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996016051-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | SLC10A2, SLC10A1, LCAT | SLC10A2 1/4885 |
| US-20240067617-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.